Leidos reported three-month revenues of $4,630 million and net income of $413 million for October 2, 2026, while total backlog reached $49,554 million. Cash was $630 million and debt $6.0 billion.
LDOS · Leidos Holdings, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Leidos generated $4.63 billion revenue, up 4%, and $413 million net income in the third quarter. Full-year revenue guidance was reduced to $18.00 - $18.20, while non-GAAP diluted EPS guidance increased to $12.50 - $12.70.
Leidos reported third-quarter revenue of $4.63 billion, up 4%, non-GAAP diluted EPS of $3.62, up 19% year-over-year, and $476 million of free cash flow. It enhanced 2026 guidance, while VBA contract changes drove Health contraction.
Leidos Holdings, Inc. closed the Nickel JV Ultimate Parent, LLC transaction on October 5, 2026, contributing the SES/IA Business for 41.5% equity while AHP Entities received 58.5%; the AHP Investor will appoint a majority of the board.
Leidos Holdings, Inc. elected Jeffery S. McElfresh to its board effective October 1, 2026, increasing the board to 11 members and assigning him to the Corporate Governance and Ethics and Technology and Information Security Committees.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 3, 2026TL;DR. Leidos delivered 4% revenue growth, 19% non-GAAP EPS growth, higher adjusted EBITDA margin, 22% funded-backlog growth, higher EPS and operating-cash-flow guidance, and major new bookings and awards. Offsetting those gains, revenue guidance was lowered, Health revenue, margins and backlog weakened, cash generation declined, interest expense increased, nine-month operating results weakened, organic growth was only 0.6%, and transaction costs affected results.
- + Revenue increased 4% year over year to $4.63 billion.
- + Non-GAAP diluted EPS increased 19% year over year to $3.62.
- + Adjusted EBITDA increased 5% year over year to $644 million, while margin improved to 13.9% from 13.8%.
- + Funded backlog increased 22% year over year to $11.1 billion.
- − Strategic corporate transactions resulted in $12 million of costs in the quarter.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Research
our published analysis of this companyEquibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $1.25B | Six Months Ended July 3, 2026 | -0.2% |
| Adjusted EBITDA margin non-GAAP | 13.9% | Six Months Ended July 3, 2026 | -5.4% |
| Book-to-bill ratio | 1.1 | Q2 FY2026 | — |
| Defense backlog | $13.76B | July 3, 2026 | — |
| Defense non-GAAP operating margin non-GAAP | 9.9% | Three Months Ended July 3, 2026 | — |
| Entrust backlog acquired | $371M | March 27, 2026 | — |
| Free cash flow conversion ratio | 185% | Q2 FY2026 | — |
| Funded backlog | $10.22B | As of July 3, 2026 | — |
| Health backlog | $6.61B | July 3, 2026 | — |
| Health non-GAAP operating margin non-GAAP | 23.8% | Three Months Ended July 3, 2026 | — |
| Homeland backlog | $9.93B | July 3, 2026 | — |
| Homeland non-GAAP operating margin non-GAAP | 12.1% | Three Months Ended July 3, 2026 | — |
| Intelligence & Digital backlog | $18.41B | July 3, 2026 | — |
| Intelligence & Digital non-GAAP operating margin non-GAAP | 10.1% | Three Months Ended July 3, 2026 | — |
| Net bookings | 4.9B | Q2 FY2026 | — |
| Non-GAAP Diluted Earnings per Share non-GAAP | $3.26 | Q2 FY2026 | — |
| Non-GAAP diluted EPS non-GAAP | $6.39 | Six Months Ended July 3, 2026 | — |
| Non-GAAP Free Cash Flow non-GAAP | 761M | Q2 FY2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 793M
-32M Payments for property, equipment and software
= Non-GAAP free cash flow 761M
|
|||
| Non-GAAP net income attributable to Leidos common stockholders non-GAAP | $411M | Three Months Ended July 3, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income attributable to Leidos common stockholders 354M
+26M Acquisition, integration and restructuring costs
+30M Amortization of acquired intangibles
+1M Asset impairment charges
= Non-GAAP net income attributable to Leidos common stockholders 411M
|
|||
| Non-GAAP operating income non-GAAP | $1.16B | Six Months Ended July 3, 2026 | — |
| Non-GAAP operating margin non-GAAP | 12.9% | Six Months Ended July 3, 2026 | — |
| Operating cash flow conversion ratio | 224% | Q2 FY2026 | — |
| Total backlog | $48.71B | As of July 3, 2026 | — |
| Trailing-twelve-month book-to-bill | 1.1 | Q2 FY2026 | — |
| Unfunded backlog | $38.49B | As of July 3, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Information Technology Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LDOS
this stock
Leidos Holdings, Inc.
|
$15.86B | -27.9% | +3.1% | 11.6 | 3.2% |
|
IBM
International Business Machines Corp
|
$229.20B | -18.1% | +7.6% | 20.6 | 1.9% |
|
ACN
Accenture plc
|
$165.72B | -7.7% | +6.5% | 18.3 | 3.2% |
|
INFY
Infosys Ltd
|
$49.86B | -30.9% | — | — | 2.1% |
|
CTSH
Cognizant Technology Solutions Corp
|
$27.85B | -25.0% | +7.0% | 11.4 | 5.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 3, 2026
- This year
- 21
Leidos reported three-month revenues of $4,630 million and net income of $413 million for October 2, 2026, while total backlog reached $49,554 million. Cash was $630 million and debt $6.0 billion.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LDOS | -4.2% | +3.2% | -0.5% | -9.1% | -27.9% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -2.5% | +6.6% | +0.9% | -7.0% | -36.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.